1133433-92-7Relevant articles and documents
Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834
Young, Wendy B.,Barbosa, James,Blomgren, Peter,Bremer, Meire C.,Crawford, James J.,Dambach, Donna,Gallion, Steve,Hymowitz, Sarah G.,Kropf, Jeffrey E.,Lee, Seung H.,Liu, Lichuan,Lubach, Joseph W.,Macaluso, Jen,Maciejewski, Pat,Maurer, Brigitte,Mitchell, Scott A.,Ortwine, Daniel F.,Di Paolo, Julie,Reif, Karin,Scheerens, Heleen,Schmitt, Aaron,Sowell, C. Gregory,Wang, Xiaojing,Wong, Harvey,Xiong, Jin-Ming,Xu, Jianjun,Zhao, Zhongdong,Currie, Kevin S.
, p. 1333 - 1337 (2015/03/14)
SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but wi
CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
-
Page/Page column 21; 23, (2009/04/24)
Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are de
